Boris Simkovich's Archive

Boris is the President of Light Knowledge Resources and Publisher of the Myeloma Beacon. Boris co-founded LKR in 2005 when the firm started developing its first website, an Internet search service. Boris has a B.S. in Nuclear Engineering from Penn State and a Ph.D. in Economics from Harvard. In his free time, Boris enjoys watching movies and reading.

Boris Simkovich has written 17 article(s) .

[ by | May 9, 2014 10:17 am | 46 Comments ]
Common Solvent Appears To Have Anti-Myeloma Activity

A solvent used extensively for both industrial as well as pharma­ceutical pur­poses may have substantial anti-myeloma activity.

This is the conclusion of a recent study by an international team of re­searchers, which carried out a wide range of pre-clinical investigations of the solvent N-methyl-2-pyrrolidone (NMP).

The scientists looked at the effect of NMP on myeloma cells in laboratory cul­tures as well as in mice implanted with myeloma cells. Their testing indicates that safe doses of NMP may have anti-myeloma activity …

Tags: , , , ,
Read the full story »
[ by | Apr 28, 2014 11:41 am | 2 Comments ]
Siltuximab (Sylvant) Gains FDA Approval ... But Not For Multiple Myeloma

Siltuximab, a drug that has been tested as a potential new treatment for multiple myeloma, was approved last week by the U.S. Food and Drug Administration (FDA).

Its approval, however, was as a new treatment for a form of Castleman's dis­ease, a rare disorder similar to lymphoma.

Siltuximab will be marketed in the United States by the Janssen Biotech division of Johnson & Johnson (NYSE:JNJ).  The drug's brand name will be Sylvant.

Johnson & Johnson also has submitted an application …

Tags: , , , ,
Read the full story »
[ by and | Mar 29, 2014 12:03 pm | 6 Comments ]
Large Study Sheds New Light On Tissue-Type Mismatches And Their Impact On Donor Stem Cell Transplant Outcomes

Significant improvements in donor stem cell trans­planta­tion have been made in recent years. As a result, donor trans­planta­tion – a procedure during which a patient receives stem cells from a healthy donor – has become safer and typically more successful for patients.

The majority of patients undergoing donor stem cell trans­planta­tion receive stem cells from unrelated donors. In these cases, a close match between donor and recipient tissue types is known to play an important important role in trans­plant outcomes. …

Tags: , , , , , ,
Read the full story »
[ by and | Dec 30, 2013 11:48 pm | 2 Comments ]
Further Evidence Of A Positive Link Between Weight At Diagnosis And Survival In Multiple Myeloma Patients

In a recent study conducted in Korea, investigators found that myeloma patients who had higher weights at diagnosis had the longest survival.

Patients who were underweight at diagnosis, on the other hand, had the lowest survival.

The results of the Korean study are similar to those reported by a recent study that examined weight at diagnosis and its impact on survival in U.S. veterans diagnosed with myeloma (see related Beacon news).

In the Korean study, investigators retrospectively analyzed data for …

Tags: , , , , , , ,
Read the full story »
[ by | Oct 28, 2013 2:28 pm | 5 Comments ]
Clinical Trial To Test Fenofibrate (Tricor) As Anti-Myeloma Therapy

Researchers at the University of Miami's Sylvester Cancer Center have started a Phase 2 clinical trial to test whether the cholesterol drug fenofibrate (Tricor) is effective, on its own, as an anti-myeloma therapy.

The trial is motivated by a preclinical study, which found that fenofibrate is toxic to multiple myeloma cells.  In particular, fenofibrate appears to interfere with the ability of myeloma cells to purge themselves of proteins they produce.  The proteins eventually accumulate within the cells to levels that …

Tags: , , ,
Read the full story »